Airway Vista 2022

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

About Novartis Korea

Novartis Korea (www.novartis.co.kr) is the Korean operation of Novartis, the global leading pharmaceutical company, with about 580 employees including those from Sandoz, the generic pharmaceuticals division. For the past 10 years, Novartis Korea has conducted about 200 clinical trials in Korea through active cooperation with local researchers, showing its strong commitment to R&D activities, and has made various contributions to CSR activities such as ‘CHEER YOU’, an emotional support program for patients and their families, ‘I-Eum’, a patient returnship program, ‘Gahwamomsasung’, a support program for women with cancer, and “Community Partnership Day”, an annual voluntary work participated by all employees, and putting its best effort to become a good corporate citizen that contributes to the local community.

Enerzair

Enerzair Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbation) in the last year. Enerzair Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.